Spots Global Cancer Trial Database for genital wart
Every month we try and update this database with for genital wart cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Low Dose Cyclophosphamide Treats Genital Warts | NCT00999986 | Genital Wart | cyclophosphamid... | 18 Years - 60 Years | Huazhong University of Science and Technology | |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04425291 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 4-valent HPV Va... 9-valent HPV Va... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | NCT05371353 | HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3 | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | ||
| Education, Immigration and HPV Vaccination: an Informational Randomized Trial | NCT04905030 | Cervical Cancer Vulvar Cancer Anus Cancer Penis Cancer Mouse Papilloma Head Cancer Genital Wart Neck Cancer | Information T1 Information T2 Information C | - | Karolinska Institutet | |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05584332 | Cervical Cancer Genital Wart CIN1 CIN2 CIN3 Vain I Vain III Vin I Vin II Vin III AIS VAIN - Vaginal ... | Quadrivalent Hu... Placebo | 18 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | NCT04895020 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent HPV va... | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | NCT05518201 | Penile Cancer Anal Cancer PIN-1 PIN-2 PIN-3 AIN1 AIN2 AIN3 Genital Wart | Placebo among 1... Placebo among 9... | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Low Dose Cyclophosphamide Treats Genital Warts | NCT00999986 | Genital Wart | cyclophosphamid... | 18 Years - 60 Years | Huazhong University of Science and Technology | |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | NCT05027776 | HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3 | 2-doses Group a... 3-doses Group a... 3-doses Group a... | 9 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients | NCT03153566 | Genital Wart | tuberculin cryotherapy | 20 Years - 60 Years | Assiut University | |
| Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | NCT05580341 | Cervical Cancer Genital Wart CIN VIN Papillomavirus ... | Zerun HPV-9 GARDASIL ®9 | 16 Years - 26 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Safety and Efficacy of Laser Therapy in Gynaecology | NCT04073082 | Herpes Genitali... Genital Wart Lichen Sclerosu... Cervical Intrae... Labial Reductio... Episiotomy Scar Bartholin Cyst Hidradenitis Su... | 18 Years - | Juna d.o.o. | ||
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | NCT05518201 | Penile Cancer Anal Cancer PIN-1 PIN-2 PIN-3 AIN1 AIN2 AIN3 Genital Wart | Placebo among 1... Placebo among 9... | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04422366 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent Human ... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
